Risk of important clinical outcomes with dabigatran 150 mg twice daily versus adjusted warfarin therapy that has a good or excellent level of control
| Outcome, dabigatran vs warfarin . | cTTR of 65.5%-72.6%, HR (95% CI) . | cTTR of > 72.6%, HR (95% CI) . |
|---|---|---|
| Stroke and systemic embolism (primary outcome) | 0.69 (0.44-1.09) | 0.95 (0.65-1.48) |
| Stroke, systemic embolism, pulmonary embolism, myocardial infarction, or cardiovascular death | 0.94 (0.72-1.22) | 1.19 (0.90-1.57) |
| Total death | 0.98 (0.75-1.28) | 1.08 (0.81-1.44) |
| Major bleeding | 1.13 (0.87-1.48) | 1.16 (0.88-1.54) |
| Intracranial bleeding | 0.35 (0.15-0.82) | 0.39 (0.18-0.84) |
| Major gastrointestinal bleeding | 2.26 (1.50-3.40) | 2.00 (1.25-3.21) |
| Outcome, dabigatran vs warfarin . | cTTR of 65.5%-72.6%, HR (95% CI) . | cTTR of > 72.6%, HR (95% CI) . |
|---|---|---|
| Stroke and systemic embolism (primary outcome) | 0.69 (0.44-1.09) | 0.95 (0.65-1.48) |
| Stroke, systemic embolism, pulmonary embolism, myocardial infarction, or cardiovascular death | 0.94 (0.72-1.22) | 1.19 (0.90-1.57) |
| Total death | 0.98 (0.75-1.28) | 1.08 (0.81-1.44) |
| Major bleeding | 1.13 (0.87-1.48) | 1.16 (0.88-1.54) |
| Intracranial bleeding | 0.35 (0.15-0.82) | 0.39 (0.18-0.84) |
| Major gastrointestinal bleeding | 2.26 (1.50-3.40) | 2.00 (1.25-3.21) |
Modified from Wallentin et al13 with permission.
cTTR indicates percentage of time in the therapeutic range at center level; and HR, hazard ratio.